The negative symptoms of schizophrenia and the monoamine oxidase inhibitors
- PMID: 3103152
- DOI: 10.1007/BF00690936
The negative symptoms of schizophrenia and the monoamine oxidase inhibitors
Abstract
Thirty chronic ambulatory schizophrenic patients whose main psychopathology was characterized by the persistence of negative symptoms, such as emotional withdrawal, depressed mood, motor retardation and blunted affect were included in this project in order to evaluate the therapeutic efficacy of tranylcypromine plus chlorpromazine therapy. The results show that tranylcypromine when added to the usual dose of chlorpromazine, in many instances, induces a definite improvement in these patients' clinical condition, that such treatment is safe and it may be also useful in preventing the occurrence of extra-pyramidal symptoms.
Similar articles
-
TOXICITY REVERSED: REVERSAL OF IMIPRAMINE-MONOAMINE OXIDASE INHIBITOR INDUCED TOXICITY BY CHLORPROMAZINE.J Kans Med Soc. 1964 Jun;65:279-80. J Kans Med Soc. 1964. PMID: 14157699 No abstract available.
-
The effects of tranylcypromine and chlorpromazine upon the spontaneous motor activity of mice.Behav Neuropsychiatry. 1972 Jun-Jul;4(3-4):12-3 passim. Behav Neuropsychiatry. 1972. PMID: 5071173 No abstract available.
-
[NEW DEVELOPMENTS IN ANTIDEPRESSIVE DRUG THERAPY].Clin Eur. 1963 Mar-Apr;30:121-5. Clin Eur. 1963. PMID: 14079215 Italian. No abstract available.
-
Clinical studies with propericiazine (R.P. 8909).Dis Nerv Syst. 1967 Aug;28(8):526-31. Dis Nerv Syst. 1967. PMID: 4383004 Clinical Trial. No abstract available.
-
MONOAMINE OXIDASE INHIBITORS.Anaesthesia. 1964 Jul;19:376-86. doi: 10.1111/j.1365-2044.1964.tb00392.x. Anaesthesia. 1964. PMID: 14174638 Review. No abstract available.
Cited by
-
Pargyline reduces/prevents neuroleptic-induced acute dystonia in monkeys.Psychopharmacology (Berl). 1987;93(2):207-13. doi: 10.1007/BF00179935. Psychopharmacology (Berl). 1987. PMID: 2827216
-
Altered states, alkaloids, and catatonia: Monoaminoxidase inhibitors and their role in the history of psychopharmacology.Front Pharmacol. 2022 Dec 6;13:1053534. doi: 10.3389/fphar.2022.1053534. eCollection 2022. Front Pharmacol. 2022. PMID: 36561338 Free PMC article. Review.
-
Negative symptoms in schizophrenia: considerations for clinical trials. Working group on negative symptoms in schizophrenia.Psychopharmacology (Berl). 1994 Jun;115(1-2):221-8. doi: 10.1007/BF02244775. Psychopharmacology (Berl). 1994. PMID: 7862898 Review.
-
Histone modifications, DNA methylation, and schizophrenia.Neurosci Biobehav Rev. 2010 May;34(6):882-8. doi: 10.1016/j.neubiorev.2009.10.010. Epub 2009 Oct 30. Neurosci Biobehav Rev. 2010. PMID: 19879893 Free PMC article. Review.
-
Positive-negative symptom assessment in schizophrenia: psychometric issues and scale comparison.Psychiatr Q. 1990 Fall;61(3):163-78. doi: 10.1007/BF01064966. Psychiatr Q. 1990. PMID: 2075220 Review.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical